RAC in EU regulatory processes: RAC concludes on scientific opinions for CLH

This news update featuring RAC in EU regulatory processes is brought to you by ECHA.

 

 

The role of RAC in EU regulatory processes

 

The Committee is responsible for preparing the opinion of the Agency on applications for authorisation, proposals for restrictions and proposals for harmonised classification and labelling. RAC also prepares opinions on specific questions relating to risks of chemicals to human health or the environment and on any other aspects concerning the safety of substances at the Executive Director’s request. The final decision for proposals for harmonised classification and labelling, for proposals for restrictions as well as on applications for authorisation will be taken by the European Commission through a committee procedure.

 

At its 29th meeting from 2 to 6 June, the Committee for Risk Assessment (RAC) adopted seven opinions for harmonised classification and labelling (CLH):

 

    • 5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate (Bupirimate (ISO))

 

    • 1-methyl-2-pyrrolidone (NMP)

 

    • Propylene oxide

 

    • 1,5-pentanedial (Glutaraldehyde)

 

    • Reaction mass of bis(2,2,6,6-tetramethyl-1-octyloxypiperidin-4-yl)-1,10-decanedioate and 1,8-bis[(2,2,6,6-tetramethyl-4-((2,2,6,6-tetramethyl-1-octyloxypiperidin-4-yl)-decan-1,10-dioyl)piperidin-1-yl)oxy]octane (Tinuvin 123)

 

    • 2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione (Flumioxazin (ISO))

 

    • 1,2-dichloropropane (PDC)

 

 

 

For more information on RAC in EU regulatory prosses, please visit the ECHA link above. Please contact Nexreg for Regulatory Services.